Xu Linglong, Ding Xiaoxiao, Ying Limei, Zhang Xiaochang, Lu Nina
Department of Hematology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, People's Republic of China.
Onco Targets Ther. 2019 Sep 23;12:7833-7842. doi: 10.2147/OTT.S211436. eCollection 2019.
MYD88 mutation has been reported in various lymphomas, specifically in lymphoplasmacytic lymphoma. Yet, the mutation has not been reported in primary follicular lymphoma. Here, we present a 62-year-old male with follicular lymphoma who had an MYD88 L265P somatic mutation and monoclonal IgM gammopathy. He received four cycles of R-CHOP immunochemotherapy. Interim PET/CT evaluation indicated a state of stable disease (SD). Neither did serum IgM remarkably drop. He was then given a bortezomib-contained regimen which significantly reduced the level of serum IgM. To the best of our knowledge, this is the first report of follicular lymphoma with monoclonal IgM and MYD88 L265P mutation. The present case indicated bortezomib may benefit these patients.
MYD88突变已在多种淋巴瘤中被报道,特别是在淋巴浆细胞淋巴瘤中。然而,该突变尚未在原发性滤泡性淋巴瘤中被报道。在此,我们报告一例62岁的滤泡性淋巴瘤男性患者,其存在MYD88 L265P体细胞突变和单克隆IgM丙种球蛋白病。他接受了四个周期的R-CHOP免疫化疗。中期PET/CT评估显示疾病稳定(SD)状态。血清IgM也未显著下降。随后他接受了含硼替佐米的方案治疗,该方案显著降低了血清IgM水平。据我们所知,这是首例伴有单克隆IgM和MYD88 L265P突变的滤泡性淋巴瘤报告。本病例表明硼替佐米可能使这些患者获益。